For laboratory research only. Not for human consumption.Our comparison method ↗
Studio-style Deals on Peptides product visual for AOD-9604

Vial comparison

AOD-9604 prices

Compare AOD-9604 listings by strength, selection and supplier. Inspect the original source behind each price.

33suppliers represented
43source-linked listings
5strengths available

MATCH SIZE AND QUANTITY

Build your comparison.

Daily snapshot · inspect sources

Choose a labeled amount and selection to load matching prices.

GO BEYOND THE PRICE

Track it. Plan it. Inspect it.

Select a strength and selection above to view price history, save a price watch or add it to your basket.

DOCUMENTATION PASSPORTS

Reports and batch records

Search all batch records

Inspect the source report, recorded lot and document access. A report link does not confirm the batch currently shipping.

Loading documentation records…

Listed amounts and selections

  • 2 mg2 suppliers · Pack counts: 1
  • 5 mg30 suppliers · Pack counts: 1, 2, 3, 10
  • 6 mg1 supplier · Pack counts: 1
  • 10 mg4 suppliers · Pack counts: 1
  • 12 mg1 supplier · Pack counts: 1

Reported quantities in this family: 1, 2, 3, 10. Counts and units must be matched to the exact listing.

Compare the exact selection

Choose the labeled amount per unit and quantity before comparing. A single unit and a multipack have different upfront prices. Keep product format and exact recipe consistent; similar names do not establish equivalent products.

Follow the original listing to check its quantity, availability and current price. Unit prices use the full labeled mass in each selection.

Single-vial price overview

Compare within each strength. Every row covers one vial and includes only listings marked in stock with known quantities.

Listed total prices before additional promotions or coupon estimates. Includes supplier captures and aggregator reports; capture dates do not confirm current vendor price or stock. Shipping and tax extra. Open the source before relying on a price.
StrengthSelectionLowest listed total pricePrice per mgSupplier countCompare
2 mg1 vial$25.00$12.502Compare
5 mg1 vial$19.24$3.8527Compare
6 mg1 vial$72.25$12.041Compare
10 mg1 vial$48.99$4.903Compare
12 mg1 vial$37.39$3.121Compare

Suppliers with AOD-9604 listings

33 profiles
View 27 more supplier profiles

Sources and comparison limits

4 listings from direct supplier captures and 39 listings from aggregator reports. Capture and import dates record when data was obtained; they do not guarantee the supplier’s current price or stock.

Listings include out-of-stock and unconfirmed-stock records. Inclusion does not certify a supplier, a batch or a product. Read how matching and source dates work.

Explore more vial listings

Browse all products

FROM PEPTIDES CALCULATOR

About AOD9604

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

AOD-9604 is a 16-amino-acid peptide taken from the tail end of human growth hormone, residues 177 to 191, with a tyrosine added at the front to stabilize it and a disulfide bond closing a loop between its two cysteines. It came out of Monash University in Melbourne and was developed by Metabolic Pharmaceuticals as an oral obesity tablet across six trials in roughly 900 people between 2001 and 2006, none of which showed a convincing weight-loss effect. The pivotal 24-week study missed its primary endpoint and the company ended obesity development in February 2007; the molecule was later renamed LAT8881 by Lateral Pharma and tested for nerve pain, where it again failed to separate from placebo. It is approved nowhere, is prohibited by WADA, and an FDA advisory committee voted in December 2024 against adding it to the list of substances allowed in pharmacy compounding.

Formula
C78 H123 N23 O23 S2
Molar mass
1,815.1 g/mol
CAS number
221231-10-3
Amino acids
16

Research evidence described in the source

Human

Six-trial safety summary

Published pooled safety reporting found no GH-like IGF-1 or glucose signal over the studied periods.

Human

Phase 2b efficacy failure

Development for obesity stopped after no significant weight-loss benefit in the larger 24-week study.

Animal

Preclinical lipolysis signal

Rodent findings motivated clinical development but did not translate into pivotal efficacy.

Limitations noted in the source

  • A tolerability signal is not evidence of efficacy.
  • The pivotal negative trial is central to interpreting marketing claims.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
Publications and references linked by the source

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.